Evidence map›Paper›PMID 34866921›Full record

ReviewInfection and drug resistance2021

Therapeutic Uses of Traditional Chinese Medicines Against COVID-19.

Manal Buabeid, Munazza Ijaz, Saba Shamim, Xianju Huang, Ghulam Murtaza

Abstract readReview
In one paragraph

Review in Infection and drug resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Manal Buabeid *College of Pharmacy and Health Sciences, Ajman University, Ajman, 346, United Arab Emirates.ORCID 0000-0002-5519-1698
Munazza Ijaz *Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
Saba ShamimInstitute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
Xianju HuangCollege of Pharmacy, South-Central University for Nationalities, Wuhan, 430074, People's Republic of China.ORCID 0000-0002-0218-6983
Ghulam MurtazaDepartment of Pharmacy, COMSATS University Islamabad, Lahore Campus, Lahore, 54000, Pakistan.ORCID 0000-0001-5649-5768

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is a pandemic and a serious respiratory disorder that is caused by coronavirus. It has produced an outbreak of acute infectious pneumonia in China and afterward all around the world. There is not a single anti-viral drug, vaccine or any kind of treatment available for this fatal disease. There are only a few options available for symptomatic relief. Thus, in China, 85% of SARS-CoV-2 infected individuals have been treated with traditional Chinese medicines (TCM). Thus, this article focused on the previous kinds of literature regarding COVID-19 and its treatment with TCM along with its applications. SARS-CoV-2 and SARS-CoV showed similarity in genes, pathological processes, and epidemiology, so these can be treated with TCM. The proof regarding treatment of SARS-CoV with TCM explicitly shows the advantages of using TCM therapy for COVID-19. Present literature explains the mode of action and efficacy of TCM and elaborates on the natural compounds introduced to treat COVID-19.

Indexed as

antiviralsCOVID-19efficacymode of actionrespiratory pneumoniaTCM

Identifiers

PMID34866921
PMCPMC8639285

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.